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Porcine T-cell recognition of foot-and-mouth disease virus (FMDV) nonstructural proteins (NSP) was tested
using in vitro lymphoproliferative responses. Lymphocytes were obtained from outbred pigs experimentally
infected with FMDV. Of the different NSP, polypeptides 3A, 3B, and 3C gave the highest stimulations in the in
vitro assays. The use of overlapping synthetic peptides allowed the identification of amino acid regions within
these proteins that were efficiently recognized by the lymphocytes. The sequences of some of these antigenic
peptides were highly conserved among different FMDV serotypes. They elicited major histocompatibility com-
plex-restricted responses with lymphocytes from pigs infected with either a type C virus or reinfected with a het-
erologous FMDV. A tandem peptide containing the T-cell peptide 3A[21–35] and the B-cell antigenic site VP1
[137–156] also efficiently stimulated lymphocytes from infected animals in vitro. Furthermore, this tandem pep-
tide elicited significant levels of serotype-specific antiviral activity, a result consistent with the induction of anti-
FMDV antibodies. Thus, inclusion in the peptide formulation of a T-cell epitope derived from the NSP 3A pos-
sessing the capacity to induce T helper activity can allow cooperative induction of anti-FMDV antibodies by B cells.
The identification and characterization of T-cell epitopes
is important for understanding protective immunity against
pathogens mediated by CD81 lymphocytes as well as CD41
lymphocyte activities (3). Recognition of T-cell epitopes by
lymphocytes from different species and individuals is restricted
by the polymorphism of the major histocompatibility complex
(MHC) molecules, which are responsible for the presentation
of foreign antigens by antigen-presenting cells (25). Therefore,
the identification of T-cell epitopes capable of inducing an
effective response, while being widely recognized by MHC
alleles frequent in natural populations of host species, is a
problem for the development of new vaccines, particularly
those based on synthetic peptides (41).
Foot-and-mouth disease virus (FMDV) is a picornavirus
that produces a highly contagious disease of cloven-hoofed
farm animals (36). The FMDV particle contains a positive-
strand RNA molecule of about 8,500 nucleotides, enclosed
within an icosahedral capsid comprising 60 copies each of four
virus proteins VP1 to VP4 (reviewed in reference 4). The
genome encodes a unique polyprotein from which the different
viral polypeptides are cleaved by viral proteases (46), including
nine different mature nonstructural proteins (NSP). Each of
these NSP, as well as some of the precursor polypeptides, are
involved in functions that are relevant to the virus life cycle in
infected cells (reviewed in reference 37). FMDV shows a high
genetic and antigenic variability, which is reflected in the seven
serotypes and the numerous variants described to date (re-
viewed in reference 22). FMD control is mainly implemented
by using chemically inactivated whole virus vaccines (reviewed
in reference 5). Viral infection and immunization with conven-
tional vaccines usually elicit high levels of circulating neutral-
izing antibodies, which correlate with protection against the
homologous and antigenically related viruses (54). However,
chemically inactivated vaccines have a number of disadvan-
tages. Among these are the requirement for a cold chain to
preserve capsid stability, the need for periodic re vaccination
with virus strains antigenically similar to the circulating viruses,
and the risk of virus release during vaccine production (5).
These limitations have led to the search of alternative, safe
immunogens.
The antigenic structure of the virus recognized by B lym-
phocytes has been characterized in detail (reviewed in refer-
ences 10 and 30), from which the main B-cell epitopes are seen
to be located in defined structural motives exposed on the
surface of the capsid (2). A region located in the G-H loop, at
positions 140 to 160 of capsid protein VP1, has been identified
as the main continuous viral epitope recognized by host B
lymphocytes to produce neutralizing antibodies (6, 9). Peptides
spanning VP1 residues 140 to 160 retain reactivity with neu-
tralizing monoclonal antibodies (MAbs) and induce neutraliz-
ing antibodies when used as immunogens (6, 9, 10, 30). How-
ever, VP1, either purified from virions or expressed in different
systems, has been shown to be a poor immunogen in terms of
production of neutralizing antibodies and protection, probably
due to an unproper exposure of site A (9, 22). The B-cell site
A has been widely used as an immunogenic peptide (reviewed
in reference 9). DiMarchi et al. (21) reported protection
against virus challenge infection in cattle immunized with a
peptide in which the VP1 residues 140 to 160 were colinearly
synthesized with those corresponding to VP1 residues 200 to
213. However, further results involving larger number of ani-
mals have shown that these peptides afford limited protection
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in natural hosts (51). One of the limiting factors of peptide
vaccines may be the absence of T-cell epitopes capable of
inducing the T-cell help required in cooperation with immune
B lymphocytes for the production of specific antibody (15, 41,
48). The induction of anti-FMDV antibodies is T cell depen-
dent (18). In recent years, several T-cell epitopes recognized by
cattle and swine lymphocytes have been identified in the
FMDV capsid proteins (7, 17, 39, 55). Inclusion of one of these
T-cell epitopes identified in VP1 residues 21 to 40 in a tandem
peptide with the B-cell site A has been shown to overcome
individual nonresponsiveness of cattle to peptide A (17). How-
ever, the recognition of this and other T-cell epitopes identi-
fied in FMDV capsid proteins is significantly restricted by the
MHC polymorphism of the host species (24, 26, 39), and their
potential to improve synthetic vaccines is, therefore, limited.
Yet T-cell epitopes relevant to the induction of a protective
response have also been described in the NSP of several vi-
ruses (13, 27). Consequently, an extension of analysis of T-cell
epitopes to FMDV NSP offers the possibility to broaden the
repertoire of viral epitopes recognized by host immune de-
fenses. In addition, the low degree of amino acid variation in
NSP among different FMDV serotypes should enable the iden-
tification of T-cell epitopes recognizable in a heterotypic man-
ner, an important requirement for inclusion in a synthetic
vaccine against this virus.
We therefore analyzed the heterotypic lymphoproliferative
responses against different NSP, using lymphocytes from FMDV-
infected pigs. For the NSP 3A, 3B, and 3C, which consistently
induced higher responses, overlapping synthetic peptides were
employed to identify MHC class II-restricted T-cell sites. A
tandem peptide including the B-cell antigenic site VP1[137–
156] colinearly synthesized with one of this T-cell peptides,
corresponding to 3A residues 21 to 35, was capable of eliciting
significant levels of serotype-specific antiviral activity, a finding
consistent with the induction of anti-FMDV antibodies.
MATERIALS AND METHODS
Experimental infections. Ten Landrance 3 Large White pigs, 3 to 4 months
old (obtained from different litters), were inoculated by intradermal injection of
105 PFU of a type C FMDV isolate (C-S8) into the coronary matrix of the foot.
All of the animals were free of previous FMD contact, as confirmed by the
absence of detectable anti-FMDV antibodies in the serum. At 120 days postin-
fection (p.i.), all pigs were reinfected with 105 PFU of a type O FMDV isolate
(O-BFS). In all cases, infections and reinfections resulted in fever and lesion
(vesicle) development from day 2 p.i. One animal inoculated with phosphate-
buffered saline (PBS) was used as a negative control.
Fusion proteins. Different NSP, as well as the VP1 capsid protein from a type
O FMDV isolate (O1Kb), were expressed in Escherichia coli, as fusion proteins
with the N-terminal part of MS2 polymerase (49). Figure 1A shows the viral
polypeptides used in this study. Proteins were obtained from heat-induced bac-
terial cultures by sonication and purification using 7 M urea. Viral polypeptides
were tested in lymphoproliferative assays as described elsewhere (39). Briefly, 20
mg of each polypeptide was separated using discontinuous 12% polyacrylamide
gel electrophoresis (wt/vol) gels and transferred onto nitrocellulose sheets. The
different viral polypeptides were identified by Western blotting using protein-
specific rabbit antisera (38). Nitrocellulose fragments containing individual viral
polypeptides, as well as control fragments containing nonviral proteins, were
solubilized in dimethyl sulfoxide as described earlier (1) and used in the prolif-
eration assays.
Peptide synthesis. A total of 83 pentadecapeptides covering the entire 3ABC
precursor sequence of FMDV isolate C-S8 (29, 53) and overlapping each other
by 10 residues were prepared. Their sequences and locations on the correspond-
ing NSP are shown in Table 1. The peptides were synthesized in N-terminal free,
C-terminal carboxamide form by 9-fluorenylmethoxy carbonyl-based solid-phase
methods (32) in an Abimed 422 multiple synthesizer, as previously described
(31). After trifluoroacetic acid cleavage, the crude materials were analyzed for
identity by MALDI-TOF (matrix-assisted laser desorption ionization–time of
flight) mass spectroscopy and for purity by reversed-phase high-pressure liquid
chromatography (HPLC). They were found to be correct by both criteria. Any
sequences that failed to give the expected mass and/or that showed ,75% purity
by HPLC were resynthesized under carefully controlled conditions (manual
assembly, ninhydrin monitoring, recoupling as required) until the above require-
ments were met.
In addition, two tandem peptides containing the sequence of the continuous
B-cell epitope VP1[137–156] juxtaposed to the T-cell epitope 3A[21–35], in the
two possible orientations (peptides BT and TB; Table 1), were prepared. Both
peptides were synthesized as C-terminal carboxamides by Boc-based solid-phase
methods (12) in semiautomated mode, with systematic ninhydrin control and
recoupling as required. Preliminary deprotection-cleavage experiments (HF–p-
cresol, 9:1, 0°C, 1 h) showed substantial oxidation to sulfoxide of the Met residue
in each sequence. In order to minimize this side reaction, acidolysis of the
peptide resins was conducted under low-high hydrogen fluoride conditions (52).
Even so, crude complexes were obtained in both cases, requiring two consecutive
reversed-phase HPLC purification steps to give fairly homogeneous (.90%)
products, with correct amino acid analysis and MALDI-TOF mass spectral data.
B-cell antigenicity of these tandem peptides was confirmed as they reacted in dot
blot assays against MAbs that recognized the peptide VP1[137–156] (7).
Lymphoproliferation assays. Proliferation assays with porcine lymphocytes
were performed as described elsewhere (39). Blood was collected in 5 mM EDTA
and used immediately for the isolation of peripheral blood mononuclear cells
(PBMC) (45). Assays were performed in 96-well round-bottom microtiter plates
(Nunc). Briefly, 2.5 3 105 PBMC per well were cultured in triplicate, in a final
volume of 200 ml, in complete RPMI, 10% (vol/vol) fetal bovine serum, and 50
mM 2-mercaptoethanol in the presence of various concentrations (fivefold dilu-
tions) of the following: FMDV, ranging from 4 3 103 to 2.5 3 106 PFU/ml;
nitrocellulose-bound viral polypeptides, ranging from 0.02 to 2.5 mg/ml; and
synthetic peptides, ranging from 0.8 to 100 mg/ml. Control cultures without viral
antigens were included. Cells were incubated at 37°C in 5% CO2 for 4 days. After
incubation, each well was pulsed with 0.5 mCi of [methyl-3H]thymidine for 18 h.
The cells were collected using a cell harvester, and the incorporation of radio-
activity into the DNA was measured by liquid scintillation in a Microbeta counter
(Pharmacia). Results were expressed as stimulation indexes (SI) (mean counts
per minute [cpm] of stimulated cultures/mean cpm of control cultures). Lym-
phoproliferations that induced SI of $3 were considered as positive.
For the analysis of the role played by the MHC in the lymphoproliferations,
the following murine anti-swine MHC swine leukocyte antigen (SLA) MAbs
were used: 74-11-10 (immunoglobulin G [IgG2b]) anti-SLA class I (35) and
MSA-3 (IgG2a) anti-SLA class II (28). The procedure was as described previ-
ously (7). A total of 15 ml of the appropriate MAb (1 mg/ml) was added per well
of PBMC, stimulated with peptides as described above, at the beginning of
culture, and an additional 15 ml per well was added after 24 h. Finally, the plates
were processed as described above. These concentrations had been identified to
give maximum specific blocking of SLA-restricted responses and have been
successfully employed to such ends (7). The anti-MHC class II MAb concentra-
tions have been shown to inhibit concanavalin A-, but not phorbol esters plus
PMA ionophore (PMA)-, induced proliferation of swine PBMC, while the anti-
MHC class I MAb did not affect these proliferations (11). Under the experimen-
tal conditions used, FMDV peptide-induced lymphoproliferations were not sig-
nificantly inhibited by MAbs against the SWC3 monocytic marker and the
gdTCR which acted as relevant negative controls (7).
Detection of FMDV neutralizing activity in supernatants of immune PBMC
stimulated with peptides. About 106 PBMC from reinfected pigs were in vitro
stimulated, as described above, with 20 mg of the different peptides per ml.
PBMC from infected animals incubated in the presence of medium alone were
used as controls. Culture supernatants were collected after 4, 7, and 13 days of
stimulation, and the FMDV neutralizing activity was analyzed using a modifica-
tion of the PFU reduction assay previously described (40). Briefly, ca. 60 to 80
FMDV PFU were incubated for 45 min, with or without 125 ml of the superna-
tants. The mixtures were employed to infect BHK-21 cell monolayers (ca. 106
cells), and the infection was allowed to proceed for 18 h in the presence of
low-melting-point agarose (1.3%). The monolayers were fixed and stained with
10% (vol/vol) acetic acid–0.5% (wt/vol) crystal violet, and virus PFU were scored.
PFU reductions were expressed as the percentage of PFU observed in the
presence of peptide-stimulated supernatants with respect to the PFU in the
presence of supernatant from PBMC incubated with medium alone.
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FIG. 1. Heterotypic lymphoproliferative response to viral polypeptides by FMDV-infected pigs. Fusion polypeptides from type O isolate (O1Kb)
were used to in vitro stimulate PBMC from pigs infected with type C isolate (C-S8), as described in Materials and Methods. (A) Schematic rep-
resentation of FMDV genomic RNA showing the location in the viral polyprotein of the fusion polypeptides used in this study. (B) Time course
study of the lymphoproliferative response to FMDV polypeptides by lymphocytes from infected pigs 1 and 2. Assays were performed with lympho-
cytes obtained at 0, 4, 10, 21, 38, 50, 63, 70, 81, and 93 d.p.i. In those d.p.i. (i.e., from 10 to 80) in which positive SI were observed, peak responses
were obtained with a nitrocellulose-bound protein concentration of 2.5 mg/ml, with the following exceptions in which the highest stimulation was
obtained at a concentration of 0.5 mg/ml: VP1, day 10 (pigs 1 and 2); 3ABC, day 50 and 63 (pig 1) and days 63, 70, and 80 (pig 2); 3C, day 63 (pig
2); and 3D, day 63 (pig 1). (C) Peak lymphoproliferative response to FMDV polypeptides by the four pigs (animals 1 to 4) analyzed. The dotted
line represent the value (SI $3), above which responses were considered positive. The d.p.i. values, followed by the nitrocellulose-bound protein
concentration (in micrograms per milliliter) corresponding to each of the responses, are shown above each bar (i.e., “70/2.5” indicates an SI ob-
tained at 70 d.p.i. with 2.5 mg of nitrocellulose-bound protein per ml). In all cases, The results are expressed as SI as described in Materials and Meth-
ods. The standard deviations of these values never exceeded 15% of the mean. A control animal was inoculated with PBS. The background cpm
values (obtained with lymphocytes incubated with medium alone) were 502 (pig 1), 293 (pig 2), 1,140 (pig 3), 971 (pig 4), and 508 (control pig 5).
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RESULTS
Lymphoproliferative responses to FMDV NSP. In order to
study the contribution of the NSP to the T-cell response elic-
ited by FMDV in swine, type O polypeptides expressed in E.
coli (Fig. 1A) were used to stimulate in vitro PBMC from four
outbred pigs (animals 1 to 4) infected with type C isolate
(C-S8). The experimental approach was designed to identify
regions conserved among different FMDV serotypes, which
were capable of inducing heterotypic T-cell responses in lym-
phocytes from domestic pigs. Lymphoproliferative responses
against the different polypeptides were monitored using PBMC
obtained from 0 to 100 days p.i. (d.p.i.). The magnitude of the
responses observed showed animal-to-animal variation, but a
consistent trend was noted. Positive lymphoproliferations (SI
$3) against NSP and VP1 capsid protein (also included in this
analysis) were detected from day 38 p.i. until day 70 p.i., and
the higher SI were observed at between 38 and 50 d.p.i. No
stimulations were observed with PBMC obtained from the
animals prior to infection (day 0 p.i.) nor from a control animal
inoculated with PBS (pig 5). Figure 1B shows the results found
with cells from the highest-responder pigs 1 and 2, which were
representative of the results obtained with cells from the four
TABLE 1. Synthetic peptides used in this study
Peptidea No. Amino acid sequenceb Residuesc Peptidea No. Amino acid sequenceb Residuesc
3A 1 ISIPSQKSVLYFLIE 1–5
2 QKSVLYFLIEKGQHE 6–20
3 YFLIEKGQHEAAIEF 11–25
4 KGQHEAAIEFFEGMV 16–30
5 AAIEFFEGMVHDSIK 21–35
6 FEGMVHDSIKEELRP 26–40
7 HDSIKEELRPLIQQT 31–45
8 EELRPLIQQTSFVKR 36–50
9 LIQQTSFVKRAFKRL 41–55
10 SFVKRAFKRLKENFE 46–60
11 AFKRLKENFEIVALC 51–65
12 KENFEIVALCLTLLA 56–70
13 IVALCLTLLANIVIM 61–75
14 LTLLANIVIMIRETH 66–80
15 NIVIMIRETHKRQKM 71–85
16 IRETHKRQKMVDDAV 76–90
17 KRQKMVDDAVNEYIE 81–95
18 VDDAVNEYIEKANIT 86–100
19 NEYIEKANITTDDQT 91–105
20 KANITTDDQTLDEAE 96–110
21 TTDDQTLDEAEKNPLE 101–115
22 LDEAEKNPLETSGAS 106–120
23 KNPLETSGASTVGFR 111–125
24 TSGASTVGFRERTLP 116–130
25 TVGFRERTLPGQKACD 121–135
26 ERTLPGQKACDDVNS 126–140
27 GQKACDDVNSEPAQP 131–145
28 DDVNSEPAQPTEEQP 136–150
29 EPAQPTEEQPQAEGP 141–155
30 TEEQPQAEGPYAGPL 146–153
3B 1 QAEGPYAGPLERQRP 1–12
2 YAGPLERQRP LKVRA 3–17
3 ERQRP LKVRAKLPRQ 8–22
4 LKVRAKLPRQE 13–23
5 GPYAGPMERQKPLKV 24–38
6 PMERQKPLKVKARAP 29–43
7 KPLKVKARAPVVKEG 34–48
8 KARAPVVKEGPYEGP 39–53
9 VVKEGPYEGPVKKPV 44–58
10 PYEGPVKKPVALKVK 49–63
11 VKKPVALKVKAKNLI 54–68
12 ALKVKAKNLIVTE 59–73
a Peptides were 15 amino acids in size and overlapped by 10 amino acids. The viral NSP corresponding to each set of peptides (3A, 3B, and 3C) is indicated.
b Peptide amino acid sequence as in reference (51).
c Amino acid positions spanned by each peptide in the corresponding protein. The carboxy-terminal residue of each NSP is underlined. Peptide 3A-30 included the
six amino-terminal residues of 3B. Peptide 3B-1 included the three carboxy-terminal residues of 3A. The sequences corresponding to VP1 and 3A, including in the
tandem peptides, are shown.
d Tandem peptides, in which the VP1 and 3A residues are indicated, were colinearly synthesized in the two possible orientations (BT and TB). The 3A sequences
are in italics.
e That is, VP1 [137–156].
f That is, 3A [21–35].
3C 1 SGAPPTDLQKMVMGN 1–15
2 TDLQKMVMGNTKPVE 6–20
3 MVMGNTKPVELILDG 11–25
4 TKPVELILDGKTVAI 16–30
5 LILDGKTVAICCATG 21–35
6 KTVAICCATGVFGTA 26–40
7 CCATGVFGTAYLVPR 31–45
8 VFGTAYLVPRHLFAE 36–50
9 YLVPRHLFAEKYDKI 41–55
10 HLFAEKYDKIMLDGR 46–60
11 YDKIMLDGRALTDS 51–65
12 MLDGRALTDSDYRVF 56–70
13 ALTDSDYRVFEFEIK 61–75
14 DYRVFEFEIKVKGQD 66–80
15 EFEIKVKGQDMLSDA 71–85
16 VKGQDMLSDAALMVL 76–90
17 MLSDAALMVLHRGNR 81–95
18 ALMVLHRGNRVRDIT 86–100
19 HRGNRVRDITKHFRD 91–105
20 VRDITKHFRDVARMK 96–110
21 KHFRDVARMKKGTPV 101–115
22 VARMKKGTPVVGVIN 106–120
23 KGTPVVGVINNADVG 111–125
24 VGVINNADVGRLIFS 116–130
25 NADVGRLIFSGEALT 121–135
26 RLIFSGEALTYKDIV 126–140
27 GEALTYKDIVVCMDG 131–145
28 YKDIVVCMDGDTMPG 136–150
29 VCMDGDTMPGLFAYR 141–155
30 DTMPGLFAYRAATKA 146–160
31 LFAYRAATKAGYCGG 151–165
32 AATKAGYCGGAVLAK 156–170
33 GYCGGAVLAKDGADT 161–175
34 AVLAKDGADTFIVGT 166–180
35 DGADTFIVGTHSAGG 171–185
36 FIVGTHSAGGNGVGY 176–190
37 HSAGGNGVGYCSCVS 181–195
38 NGVGYCSCVSRSML 186–200
39 YCSCVSRSMLLKMKA 191–205
40 RSMLLKMKAHIDPEP 196–210
41 KMKAHIDPEPHHE 201–215
BT3A-5
d TASARGDLAHLTTTHARH
LPAAIEFFEGMVHDSIK
137–156e
T3A-5B
d AAIEFFEGMVHDSIKTASAR
GDLAHLTTTHARHLP
21–35 f
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animals analyzed. In general, the responses were dose depen-
dent, and the higher SI were obtained with nitrocellulose-
bound protein at from 0.5 to 2.5 mg/ml. Figure 1C shows the
peak responses found in each of the animals analyzed. Poly-
peptides 3AB and 3C were recognized by the lymphocytes
from all the animals analyzed. Proteins 2C, 3D, and VP1 were
recognized by cells from only two of the four pigs. These re-
sults suggest the presence within the 3ABC polypeptide region
of T-cell epitopes conserved among FMDV serotypes, which
are consistently recognized by lymphocytes from domestic pigs.
Identification of T-cell epitopes in 3A, 3B, and 3C. In order
to characterize further the T-cell epitopes located in the 3ABC
region, a set of overlapping peptides (15-mer), covering pro-
teins 3A, 3B, and 3C of the C-S8 virus, was synthesized. These
peptides were employed to stimulate in vitro lymphocytes from
infected pigs (see Materials and Methods and Table 1 for
details). For this purpose, six additional pigs (animals 6 to 11)
were experimentally infected with C-S8 virus, and their PBMC
were isolated on days 14 and 28 p.i. None of the peptides
induced positive SI in PBMC obtained from these animals
before infection (data not shown). In general, the responses
against individual peptides were already detectable at day
14 p.i., being more consistent at day 28 p.i. They were dose
dependent, and the highest values were obtained with peptide
concentrations ranging from 4 to 100 mg/ml (Table 2). Among
the 83 overlapping peptides tested, 45 did not induce signifi-
cant proliferations in any of the pigs analyzed. The peak re-
sponses against the 19 peptides that induced positive SI in at
least four of the six animals are indicated in Table 2. The
magnitude of the response against individual peptides corre-
lated with the SI observed against the whole virus, but the
pattern of peptide recognition was different in each of the
animals studied. However, three individual peptides consis-
tently stimulated PBMC from the six pigs analyzed: 3A-5[21–
35], 3C-12[56–70], and 3C-27[131–145] (see Table 2).
For studies on the T-cell antigenic specificity elicited upon
challenge, animals 7 to 11 were reinoculated 4 months after the
initial infection with a heterologous type O FMDV virus (O-
BFS). The five pigs developed an acute episode of the disease,
and PBMC obtained at days 10, 21, and 35 postreinfection
(p.r.i.) were used to perform lymphoproliferative assays in
which the 3ABC peptides were used as stimulator antigens. In
general, the responses against peptides were detected at day
21 p.r.i., being more consistent at day 35 p.r.i. The responses
were dose dependent, and the highest values were obtained
with peptide concentrations (4 to 100 mg/ml) similar to those
found with cells after the first infection (Table 3). In this
experiment, positive SI were also induced with peptide con-
centrations lower than those effective with cells from the ini-
tially infected animals (0.8 mg/ml; data not shown). The efficacy
of the heterologous restimulation showed individual variation
among the animals. A clear boost of individual peptide re-
sponses was observed for lymphocytes from animal 8. Lympho-
cytes from animals 9, 10, and 11 showed an increased, albeit of
TABLE 2. Peptides corresponding to 3A, 3B, and 3C that were
significantly recognized by lymphocytes from FMDV-infected pigs
Peptidea No. Amino acidresiduesb
SIc for pig:
6 7 8 9 10 11
3A 3 11–25 ND 5.3* 14.7 8.1* 18.2 2.5*
5 21–35 16.4 7.3* 20.2 3.2* 4.2 4.6†
6 26–40 7.6* 5.8 18.5 3.6* 14* 2.4†
9 41–55 7.3 9.7 2.8 4† 6.6 4.8*
25 121–135 ND 7.7 8.1 2.9 3.5 6.2†
3B 4 13–23 2.5 10.8 3.5 5.6* 5.2 2.2*
8 39–53 3.3 11.6 2.1 7.3† 5.5 4.3*
3C 11 51–65 ND 17.2 12.6 6.7 10.4 2.7
12 56–70 6.1* 18.6 22.4 6 4.5 5.4
13 61–75 7.1 7.8 19.7* 6.2* 2.8 7.1*
19 91–105 3† 5.5† 15.2* 6.6* 7.4 2.9*
20 96–110 2† 18.1* 2.5* 4.5* 3.6 3.9
25 121–135 9.8 16.6 14 4.3 7.7 2.5†
27 131–145 10.8* 27.4 17.3 7.3 3.2 9.2*
28 136–150 ND 14.8 10.6 3.2 4 2.7*
33 161–175 ND 15.6 4.5 3.9 6 2.9*
34 166–180 ND 16.6 18.2 4.1 15 4.4†
39 191–205 ND 5.4 2.5 7 3.5 4.2†
40 196–210 2.2 20.9 3.7 6.8 7.3 7.3
C-S8d 24.3 24.7 ND 10.7 19 ND
a Peptides that induced an SI of .3 in at least four of the six pigs analyzed. The
corresponding protein to which the peptides belong is indicated.
b Amino acid residues spanned by each of the peptides in the 3A, 3B, or 3C
NSP.
c That is, the highest SI induced by the different antigens in PBMC isolated at
day 28 p.i. Unless indicated otherwise, optimal responses were obtained with a
peptide concentration of 100 mg/ml. ND, not done. *, SI was obtained with a
peptide concentration of 20 mg/ml; †, SI was obtained with a peptide concentra-
tion of 4 mg/ml.
d SI induced by C-S8 virus. The optimal responses shown were obtained with
a viral concentration of 5 3 105 PFU/ml.
TABLE 3. Peptides corresponding to 3A, 3B, and 3C, that were
significantly recognized by lymphocytes from FMDV-reinfected pigs
Peptidea No. Amino acidresiduesb
SIc for pig:
7 8 9 10 11
3A 3d 11–25 3.2 20 4.2 28.6* 2.1*
5d 21–35 5.7 63.4 5.9* 10.6 3.3†
6d 26–40 2.6* 40.2 5* 8.5* 2.9*
9d 41–55 4.1* 13.4* 7† 6.4 1.9†
17 81–95 4.5 29.7* 4.4 19.3 1.4*
3B 2 3–17 5.5 10.1 8.4 3.5* 1.1*
4d 13–23 2.1 9.6 8 8.1 2.6*
3C 12d 56–70 4.1 93.4 17.3 5.2 9.2
13d 61–75 4.1 98.8* 13.1† 5.2 9.2*
20d 96–110 2.7 99.5 1.8* 5.4 8.7
25d 121–135 3.1 42.9* 3.5 7.1 ND
26 126–140 15.9 10.5* 4.9 4.9* ND
30 146–160 7.6 102.2 ND 6.5 ND
32 156–170 6.7 63.9 ND 5.8 ND
34d 166–180 10.2 42 2.8 33.2 10.9†
40d 196–210 8.6 10.8 8.9 4.2 11.5
C-S8e 107.5 307.9 26 56.2 ND
O-BFSe 217.3 112.4 11 52.6 ND
a Peptides that induced an SI of . 3 in at least three of the five pigs analyzed.
b Amino acid residues spanned by each peptides in the 3A, 3B, or 3C NSP.
c That is, the highest SI induced by the different antigens in PBMC isolated at
day 35 p.r.i. Unless indicated otherwise, optimal responses were obtained with a
peptide concentration of 100 mg/ml. ND, not done. *, SI obtained with a peptide
concentration of 20 mg/ml; †, SI obtained with a peptide concentration of 4
mg/ml.
d Peptides that induced positive SI in at least four of the six initially infected
pigs (see Table 2).
e SI induced by C-S8 or O-BFS viruses. The optimal responses shown were
obtained with a viral concentration of 5 3 105 PFU/ml.
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lower magnitude, in most of the SI, and the responses of
PBMC from animal 7 were lower than those observed after the
first infection. Table 3 summarizes the SI obtained with the
peptides that induced positive responses in at least three of the
five animals analyzed.
Lymphocytes from reinfected pigs responded to 11 of the 19
peptides identified as antigenic after analyses with cells ob-
tained following the first infection (Table 3). Peptides 3A-3, -5,
-6, and -9, peptide 3B-4, and peptides 3C-12, -13, -20, -25, -34,
and -40, previously identified as good stimulators (see Table 2),
also induced positive responses in at least three of the five
reinfected pigs. In addition, the following new peptides in-
duced proliferation in lymphocytes taken from the majority of
the reinfected animals analyzed: 3A-17; 3B-2; and 3C-26, -30,
and -32. Again, several individual peptides induced lympho-
proliferative responses by cells from the five animals upon
heterologous reinfection (Table 3): 3A-5[21–35], 3C-12[56–
70], 3C-13[61–75], 3C-34[166–180], and 3C-40[196–210]. Rep-
resentative dose responses induced by some of these peptides
in PBMC from infected and reinfected animals are shown in
Fig. 2.
SLA restriction of the anti-peptide response. Information
about the SLA restriction of the detected lymphoproliferative
responses was obtained using MAbs against SLA class I and
class II. These were used to inhibit in vitro the lymphoprolif-
erations induced in cells from reinfected pigs. The peptides
3A-3[11–25], 3A-5[21–35], 3C-34[166–180], and 3C-40[196–
210] were selected for this study because they induced consis-
tent responses in cells from most of the analyzed animals, after
both the first infection and the heterologous re infection (Ta-
bles 2 and 3). Results showed the highest inhibition of peptide-
induced lymphoproliferation (.75%) when the anti-SLA class
II MAb was used. This is consistent with lymphoproliferations
induced by peptides being dependent on CD41 T -helper lym-
phocyte activities (Table 4). The anti-SLA class I MAb was
also inhibitory, but the magnitude of inhibition was generally
lower than that observed with the anti-SLA class II antibody.
Antigenicity of tandem peptides including B- and T-cell epi-
topes. The potential of the T-cell epitopes identified in NSP to
improve vaccine formulation of FMDV synthetic peptides re-
quires that T-cell epitopes remain immunostimulatory when in
combination with B-cell epitopes. In order to investigate this
FIG. 2. Effect of peptide dose on the proliferative response of PBMC obtained from pigs 8, 9, and 10 at days 28 p.i. and 35 p.r.i. The values
corresponding to 0 on the x axis indicate the background of the assay (PBMC incubated with medium alone).
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point, the immunostimulatory potential of the T-cell peptide
3A-5[21–35] was further analyzed by using tandem peptides in
which this epitope was colinearly synthesized with the B-cell
site VP1[137–156]. Two possible orientations were used: pep-
tides BT and TB (Table 1). With lymphocytes from pigs 7, 9,
10, and 11, the tandem epitopes induced lymphoproliferative
responses in vitro upon infection with C-S8 virus, as shown in
Fig. 3A. The responses were dose dependent, and the highest
SI was obtained with a peptide concentration of 20 mg/ml.
Positive SI were found with cells from all four animals stimu-
lated with peptide T3A-5B, whereas only cells from animals 7
and 11 responded to peptide BT3A-5. The SI of the latter cells
were lower than those induced by peptide T3A-5B. In this ex-
periment, peptide 3A-5[21–35] was also recognized with an SI
lower than those found using peptide T3A-5B.
Upon reinfection with the heterologous O-BFS virus, lym-
phocytes from pigs 7, 8, and 10 responded to T3A-5B, again
with SI higher than those induced by peptide 3A-5[21–35]
alone (Fig. 3B). Thus, tandem peptide T3A-5B stimulates in
vitro lymphocytes from both infected and reinfected animals.
It was then interesting to address whether the incorporation
of 3A-5[21–35] into the tandem peptide could result in the
stimulation of T cells to provide the necessary immunological
help for antigen-stimulated B lymphocytes. To this end, the
stimulation of T cells by peptide T3A-5B was analyzed in terms
of cooperation with the induction of an antiviral humoral re-
sponse. Lymphocytes from reinfected pig 8 were stimulated in
vitro with peptides T3A-5B, T, or B. At different times post-
stimulation, the presence of anti-FMDV activity in the super-
natants was measured using a plaque reduction assay. Signifi-
cant PFU reductions were detected using supernatants from
cultures stimulated with peptide T3A-5B from the fourth day,
reaching a maximum with day 7 supernatants (ca90%) (Fig. 4).
The PFU reductions were higher than those obtained using
supernatants from cultures stimulated by peptides T and B
separately. In addition, the antiviral activity was restricted to
the homologous virus C-S8, since no plaque reduction was
detected when a type O FMDV was used in the assay (Fig. 4).
Thus, a serotype-specific anti-FMDV activity, consistent with
the induction of anti-FMDV neutralizing antibodies, was de-
tected upon stimulation of immune lymphocytes with peptide
T3A-5B.
DISCUSSION
In the present studies the antigenic specificity of the porcine
(an important natural host of this virus) T-cell response against
FMDV NSP was analyzed. The aim was the identification of
T-cell epitopes in NSP widely recognized by domestic pigs, the
TABLE 4. Inhibition by MAb to porcine class I and class II of
the proliferative response to 3A and 3C peptides
Peptidea MAbb
Inhibition in pigc:
9 8
Dcpm % Dcpm %
3A-3[11–25] None 8,615 6 980 4,101 6 615
Anti-class I 2,249 6 337 73.8 2,740 6 411 33.1
Anti-class II 2,850 6 484 66.9 905 6 108 77.9
3A-5[21–35] None 9,599 6 1151 7,853 6 471
Anti-class I 4,007 6 640 58.2 3,807 6 609 51.2
Anti-class II 1,938 6 193 79.8 1,525 6 213 59.9
3A-34[166–180] None 17,389 6 869 9,808 6 689
Anti-class I 5,692 6 1024 67.2 3,757 6 676 61.6
Anti-class II 2,701 6 243 84.4 2,484 6 298 74.6
3C-40[196–210] None 7,360, 6 1030 5,292 6 793
Anti-class I 2,854, 6 342 61.2 4,626 6 277 12.5
Anti-class II 1,145 6 171 84.4 2,210 6 198 58.2
a The characteristics of the peptides are described in Table 1. Peptides were
used at a concentration of 20 mg/ml. None, lymphocytes cultured in the absence
of MAb.
b A total of 15 ml (1 mg/ml) of MAb anti-SLA class I (74-11-10, Ig-G2b) or
class II (MSA-3, IgG2a) was added per well at the beginning of culture. After
24 h, the cultures were supplemented with another 15 ml of MAb.
c Lymphocytes from pigs 8 and 9, obtained at day 35 p.r.i. were used in these
experiments.
FIG. 3. Lymphoproliferative responses to peptides 3A-5[21–35],
BT3A-5, and T3A-5B. The data shown correspond to peak responses of
lymphocytes obtained at days 28 p.i. with C-S8 virus (A) and 21 p.r.i.
with the heterologous O-BFS virus (B). The standard deviations are
indicated. The peptide concentrations giving the SI shown were 20
mg/ml, except for pig 9 (in panel A) in which the peak response was
obtained with 100 mg/ml. The background cpm levels were 405 (pig 7),
450 (pig 9), 525 (pig 10), and 345 (pig 11) (A) and 302 (pig 7), 214 (pig
8), and 258 (pig 10) (B).
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sequences of which were conserved among different FMDV
serotypes. Animals were selected from different litters to en-
sure a representative sample of outbred pigs and to bring por-
cine MHC polymorphism in the T-cell epitope recognition into
the study. FMDV NSP are absent, or incorporated in very
small amounts, in the virus particle (34). Therefore, the anal-
yses used animals experimentally infected with a type C FMDV
isolate.
T-cell antigenicity of the NSP was first analyzed in terms of
the capacity of different polypeptides to stimulate in vitro T
cells from the infected animals. A heterotypic lymphoprolif-
erative response against NSP in cells from FMDV-infected
pigs was tested. Lymphoproliferations were detected from day
38 to day 70 p.i. Although the SI showed animal-to-animal
variations, polypeptides 3AB and 3C induced specific and con-
sistent responses in lymphocytes from all animals analyzed.
Polypeptides 2B and 3D and capsid protein VP1 were not
recognized by all the animals (Fig. 1C). This finding contrasts
with the recognition of type O FMDV 3D as an immunodom-
inant T-cell determinant by cattle lymphocytes, as recently
reported (16). In addition to differences between cattle and
swine in terms of antigenic recognition patterns, the lower
antigenicity of 3D for porcine lymphocytes may also reflect
differences between FMDV type C and type O. The low het-
erotypic recognition of VP1 is consistent with the sequence
divergence that exists between type O and type C FMDV.
Overlapping synthetic peptides allowed a detailed analysis
of the T-cell epitopes recognized in proteins 3A, 3B, and 3C.
Despite animal to animal variation, 19 peptides were stimu-
lated in vitro lymphocytes from, at least, four of the six infected
pigs analyzed (Table 2). The responsive peptides define T-cell
regions efficiently recognized by swine lymphocytes at the fol-
lowing amino acid positions: 3A[11–55] and -[121–135], 3B[13–
23] and -[39–53], and 3C[51–75],-[91– 110], -[121–150], -[161–
180], and -[191–210]. Eleven of these peptides were also
recognized by lymphocytes from at least three of the five het-
erotypically reinfected pigs analyzed (Table 3). Five new pep-
tides, which did not induced in vitro responses in the initially
infected animals, became responsive upon the induction of a
secondary response (Table 3). The efficacy of the heterologous
restimulation was uneven among the five animals studied. A
clear boost of individual peptide responses was only observed
for lymphocytes from animal 8. Although the number of ani-
mals used for this type of study was not sufficient for statistical
demonstration, we think that the data are consistent with the
identification of a number of peptide epitopes in the nonstruc-
tural polypeptides 3A, 3B, and 3C of FMDV, which are capa-
ble of stimulating porcine T cells following infection with vi-
ruses of different serotypes, and that some of them may boost
primed lymphocytes.
SLA class II MAb efficiently inhibited the lymphoprolifera-
tive response. This demonstrated the involvement of CD41 Th
lymphocytes in the recognition of some of the stimulatory
peptides (Table 4). Anti-class I MAb gave lower inhibitions, in
agreement with the previous reports on porcine lymphoprolif-
eration against whole virus (14, 45) and FMDV capsid protein
peptides (7). These inhibitions might relate to the high pro-
portion of CD81 CD41 double-positive cells found in swine
(58), dominated by memory Th lymphocytes (50, 59). Cer-
tainly, it must also be considered that the animals were in-
fected with FMDV and, therefore, that stimulation of CD81
cells through class I presentation could have occurred (14).
The implication of CD81 lymphocytes in protective responses
to FMDV remains largely unknown and thus its characteriza-
tion was not pursued here. Attempts to obtain porcine T-cell
clones, a highly valuable tool for understanding the antigenic
specificity and function of T cells, have had very limited suc-
cess. Thus, as a first step in the characterization of the immune
responses induced by the T-cell epitopes thus for identified,
our attention was focused on the potential of these peptides to
stimulate CD41 cells to provide T help to immune B lympho-
cytes. In this way, we attempted to identify T-cell epitopes that
could enhance the induction of anti-FMDV antibodies by pep-
tide vacines. For practical reasons, such T-cell epitopes should
be conserved among different FMDV serotypes. Peptides 3A-
3[11–25], 3A-5[21–35], 3C-25[121–135], and 3C-34[166–180]
do indeed show amino acid sequences completely conserved
among serotypes A, O, and C (Table 5). These 3A and 3C
peptides are frequently and efficiently recognized by porcine
lymphocytes in both a homotypic and heterotypic manner.
Consequently, they constitute potential candidates for inclu-
sion in a peptide vaccine formulation.
The colinear expression of T-helper and B-cell epitopes in
peptide vaccines can result in the enhancement of antibody
responses (8, 17). The design of functional combinations of
T-cell and B-cell epitopes is rather empirical (19, 47) and
should maintain the immunostimulatory ability of the B- and
T-cell components. T-cell peptide 3A-5[21–35] consistently
stimulated lymphocytes from all initially infected and rein-
fected animals analyzed in this study, as well as lymphocytes
FIG. 4. FMDV PFU reduction by supernatants of immune PBMC
stimulated in vitro with viral peptides. The data correspond to PBMC
from pig 8 (obtained at day 35 p.r.i.) assayed at different days of in vitro
stimulation with 20 mg of the indicated peptides per ml. The results are
expressed as the percent inhibition in the PFU recovered from cells
stimulated with each peptide with respect to the PFU observed with a
control supernatant incubated with medium alone. The assay was per-
formed using two FMDV isolates of different serotypes: C-S8 (type C)
and O-BFS (type O). The standard deviations are indicated.
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from four additional FMDV-infected domestic pigs (unpub-
lished results). Therefore, peptide 3A-5[21–35] was employed
to explore the potential of tandem peptides including the im-
munodominant B-cell site VP1[137–156], with either the BT or
the TB orientation, to stimulate lymphocytes from infected
animals. We first analyzed whether these tandem peptides re-
tained the capacity to induce lymphoproliferation of immune
lymphocytes. Each of the tandem peptides was recognized by
immune lymphocytes, with T3A-5B being the most efficient
stimulator of lymphocytes from both initially infected and re-
infected animals (Table 3). Different factors may mediate the
higher stimulations observed with tandem peptide T3A-5B:
among these factors is the influence of the different flanking
sequences on the binding to MHC molecules that could modify
lymphocyte activation (56) or on the susceptibility of the T-cell
epitopes to proteases in antigen processing (20).
The induction of FMDV neutralizing antibodies by immune
PBMC in response to in vitro viral stimulation has been pre-
viously reported as an indicator of T-cell–B-cell cooperation
(40). Interestingly, a significant FMDV PFU reduction activity
(up to 90%) was detected in supernatants of PBMC upon
incubation with peptide T3A-5B under conditions in which the
inhibitions induced by supernatants of PBMC stimulated with
peptide A[21–35] or 3A-5[21–35] did not exceed 20%. This
reduction was serotype specific, since it was not observed with
a type O virus (Fig. 4). These results are consistent with the
induction of anti-FMDV antibodies in the peptide-stimulated
cultures, and new experiments are being conducted to further
characterize the antiviral activity induced.
Inclusion of FMDV T-cell epitopes may enhance the immu-
nogenicity of subunit and peptide vaccines. According to the
model of intermolecular-intrastructural help (33, 43), B cells
can be activated by T cells resulting from the stimulation by
epitopes derived from a different protein, provided that both
proteins are associated in a common complex. Whether 3ABC
and viral structural proteins, VP1 in particular, may become
associated in FMDV-infected cells remains to be studied. On
the other hand, the stimulation of T cells by viral peptides may
participate not only in providing T-cell help to B lymphocytes
but also in eliciting a synergistic response against the virus
infection. T cells secrete cytokines such as gamma interferon
and interleukins that might play an important role in the pro-
TABLE 5. Alignment of the amino acid sequences corresponding to NSP 3A and 3C
Protein Virus Sequencea
z z z z z 503A C-S8 ISIPSQKSVLYFLIEKGQHEAAIEFFEGMVHDSIKEELRPLIQQTSFVKR
O-BFS
A12
z z z z z 100
C-S8 AFKRLKENFEIVALCLTLLANIVIMIRETHKRQKMVDDAVNEYIEKANIT
O-BFS R
A12 R
z z z z z 150
C-S8 TDDQTLDEAEKNPLETSGASTVGFRERTLPGQKARDDVNSEPAQPTEEQP
O-BFS K S C V
A12 T T R CN R A
z 153
C-S8 QAE
O-BFS
A12
z z z z z 50
3C C-S8 SGAPPTDLQKMVMGNTKPVELILDGKTVAICCATGVFGTAYLVPRHLFAE
O-BFS
A12
z z z z z 100
C-S8 KYDKIMLDGRALTDSDYRVFEFEIKVKRGQDMLSDAALMVLHRGNRVRDI
O-BFS V M
A12 M
z z z z z 150
C-S8 TKHFRDVARMKKGTPVVGVINNADVGRLIFSGEALTYKDIVVCMDGDTMP
O-BFS T
A12 T V
z z z z z 200
C-S8 GLFAYKAATKAGYCGGAVLAKDGADTFIVGTHSAGGNGVGYCSCVSRSML
O-BFS R
A12 S K
z z 214
C-S8 LKMKAHIDPEPHHE
O-BFS
A12 R V Q
a Amino acid substitutions in FMDV of serotypes O (O-BFS) and A (A12) with respect to the C-S8 sequence are indicated. Sequences were obtained from the
following Swiss-Prot accession numbers: Q9QCE3 (C-S8), POLG_FMDVA(A12), and POLG_FMDVO (O-BFS). Overdots indicate 10-amino-acid segments; numbers
in italics indicate the cumulative amino acid count.
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tection against the virus (23, 57). Consistent with this hypoth-
esis are the results described recently (46) that show that im-
munization with a recombinant adenovirus expressing the P1
polypeptide elicits partial protection against FMDV in pigs
and cattle in the absence of antiviral antibody response. To
explore these possibilities, experiments are in progress to as-
sess the immunogenicity in pigs of combinations of the B-cell
site VP1[140–160] and the T-cell peptides identified here.
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